EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

How I Treat Refractory CRS and ICANS Following CAR T-cell Therapy

Michael D Jain iD, Melody Smith iD, Nirali N Shah iD

Blood · 29.03.2023

DOI: 10.1182/blood.2022017414 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, online erschienen am 29.03.2023. Verfasst von Michael D Jain und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Cytokine Release Syndrome. Die Arbeit wurde bisher 119-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical use of chimeric antigen receptor (CAR) T-cell therapy is growing rapidly due to expanding indications for standard of care treatment and the development of new investigational products. The establishment of consensus diagnostic criteria for cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS), alongside the steady use of both tocilizumab and corticosteroids for treatment, have been essential to facilitating the widespread use. Pre-emptive interventions to prevent more severe toxicities has improved safety, facilitating CAR T-cell therapy in medically frail populations and those at high-risk of severe CRS/ICANS. Nonetheless, the development of persistent or progressive CRS and ICANS remains problematic, as it impairs patient outcomes and is challenging to treat. In this case-based discussion, we highlight a series of cases of CRS and/or ICANS refractory to front-line interventions. We discuss our approach to managing refractory toxicities that persist or progress beyond initial tocilizumab or corticosteroid administration, delineate risk-factors for severe toxicities, highlight the emerging use of anakinra, and review mitigation strategies and supportive care measures to improve outcomes in patients who develop these refractory toxicities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveCytokine Release SyndromeHumansConsensusInterleukin 1 Receptor Antagonist ProteinReceptors, Antigen, T-CellNeurotoxicity Syndromes

Substanzen

cell-associated neurotoxicityInterleukin 1 Receptor Antagonist ProteinReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL.
  • Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA.
  • Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

ORCID-Profile: Michael D Jain, Melody Smith, Nirali N Shah

Förderung

  • NHLBI NIH HHS
  • Intramural NIH HHS

Zitieren

APA

Jain, M. D., Smith, M., & Shah, N. N. (2023). How I Treat Refractory CRS and ICANS Following CAR T-cell Therapy. Blood. https://doi.org/10.1182/blood.2022017414

Vancouver

Jain MD, Smith M, Shah NN. How I Treat Refractory CRS and ICANS Following CAR T-cell Therapy. Blood. 2023. doi:10.1182/blood.2022017414

BibTeX
@article{Jain2023,
  author = {Jain, Michael D and Smith, Melody and Shah, Nirali N},
  title = {How I Treat Refractory CRS and ICANS Following CAR T-cell Therapy},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2022017414}
}
Kostenlos starten →